Andes Biotechnologies

Côte d’Ivoire
Kipiendouo, Zanzan District, Ivory Coast

Company profile

Andes Biotechnologies company profile

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.

Business identity

Phone number
+56223672000
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2008-01-01, Year

Headquarters

Country code
CI
Continent
Africa

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
5
Last funding
Series B / 2014-12-23
Last equity funding
Series B
Investors
2
Founders
2

Founders and investors

Founders

Luis BurzioPablo Valenzuela

Investors

AurusAustral Capital